A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Inclusion Criteria: * Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment. * Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening. * BMD T-score \</= -2.50 at the lumbar spine, total hip or femoral neck. * At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA. * Other inclusion criteria may apply. Exclusion Criteria: * Subjects with a BMD T-score \</= -4.0 at the lumbar spine, total hip, or femoral neck. * History of hip fracture. * Bone disease other than osteoporosis/ or evidence of any other clinically significant disorder, condition/ or disease or significant laboratory abnormalities. * Known sensitivity or intolerance calcium and vitamin D products. * Other exclusion criteria may apply.